Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 3,404,268 shares, a growth of 16.8% from the January 31st total of 2,915,560 shares. Based on an average daily trading volume, of 212,232 shares, the short-interest ratio is currently 16.0 days. Currently, 10.8% of the company’s stock are sold short.
A number of hedge funds have recently made changes to their positions in AST. Virtu Financial LLC raised its holdings in Asterias Biotherapeutics by 387.0% during the 4th quarter. Virtu Financial LLC now owns 71,588 shares of the biotechnology company’s stock worth $161,000 after buying an additional 56,888 shares during the period. Deutsche Bank AG grew its stake in shares of Asterias Biotherapeutics by 110.5% during the 4th quarter. Deutsche Bank AG now owns 66,180 shares of the biotechnology company’s stock worth $148,000 after acquiring an additional 34,739 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Asterias Biotherapeutics during the 4th quarter worth approximately $132,000.
Several brokerages have commented on AST. B. Riley began coverage on shares of Asterias Biotherapeutics in a report on Thursday, February 22nd. They set a “buy” rating and a $6.00 target price on the stock. Zacks Investment Research downgraded shares of Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 22nd. Finally, HC Wainwright restated a “buy” rating on shares of Asterias Biotherapeutics in a report on Wednesday, November 22nd. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $8.35.
COPYRIGHT VIOLATION WARNING: “Asterias Biotherapeutics Inc (AST) Short Interest Update” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3229290/asterias-biotherapeutics-inc-ast-short-interest-update.html.
Asterias Biotherapeutics Company Profile
Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.